FDA Lilly - Search News

News

Eli Lilly Vows to Make Weight-Loss Pill in U.S.

CBS News on MSN · 3d

Eli Lilly says GLP-1 pill for diabetes and weight loss effective in study, plans to seek FDA approval

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for diabetes and weight loss.

Money Morning · 17h

Weight Loss In a Pill Will Make Eli Lilly a $1 Trillion Stock

Pharmaceutical giant Eli Lilly (LLY) surged 14% last week to $840 per share following positive Phase 3 trial results for its oral weight-loss drug, orforglipron. With a market cap of $796 billion, LLY is the world’s most valuable healthcare company, and its trajectory suggests it could reach $1,000 per share or more by year-end 2025.

USA TODAY on MSN · 4d

Eli Lilly announces trial results of new weight loss, diabetes pill; stock booms

Eli Lilly announced the results of a clinical trial for its new pill, which the company said causes nearly 8% weight loss at certain dosages.

Asianet Newsable on MSN1h

Novo Nordisk's FDA Submission For Obesity Pill Gets Retail Traders Buzzing Amid Fierce Eli Lilly Rivalry

The request reportedly came two years after a Phase 3 study of Rybelsus, an oral formulation of semaglutide, which showed ...

2don MSN

Prediction: Eli Lilly's Newest GLP-1 Drug Will Be a Game-Changer for the Stock

Let's look at why this news could be a game-changer for Eli Lilly and its stock.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results